^
BIOMARKER:

FGFR1 overexpression

i
Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
Entrez ID:
FGFR1 overexpression
Breast Cancer
FGFR inhibitor
Sensitive: D – Preclinical
Clin Cancer Res - 2 weeks
FGFR1 overexpression
Urothelial Cancer
atezolizumab + BAY1163877
Sensitive: C2 – Inclusion Criteria
FGFR1 overexpression
RCC
sorafenib
Resistant: C3 – Early Trials
FGFR1 overexpression
Lung Cancer
ponatinib
Resistant: C3 – Early Trials
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
BAY1163877
Resistant: C3 – Early Trials
FGFR1 overexpression
NSCLC
M6123
Sensitive: D – Preclinical
FGFR1 overexpression
HER2 Negative Breast Cancer
alpelisib
Resistant: D – Preclinical
FGFR1 overexpression
HCC
lenvatinib
Resistant: D – Preclinical
FGFR1 overexpression
Liposarcoma
erdafitinib
Resistant: D – Preclinical
FGFR1 overexpression
Gastric Cancer
infigratinib
Sensitive: D – Preclinical
FGFR1 overexpression
NSCLC
anlotinib
Sensitive: D – Preclinical
FGFR1 overexpression
Lung Non-Small Cell Squamous Cancer
PRN1371
Sensitive: D – Preclinical
FGFR1 overexpression
Thyroid Gland Carcinoma
lenvatinib
Sensitive: D – Preclinical
FGFR1 overexpression
Bladder Cancer
TKI258
Sensitive: D – Preclinical
FGFR1 overexpression
Bladder Cancer
PD 0173074
Sensitive: D – Preclinical